Guillain-Barré syndrome (GBS) takes its toll on the resource poor developing countries where the incidence of GBS is several fold higher than that of Europe and North America. In Bangladesh, 15% of patients with GBS die and 20% remain unable to walk. The poor outcome of GBS in these countries is explained predominantly by the…
K. Kuitwaard1,2, E Brusse1, A.F.J.E. Vrancken4, F. Eftimov5, N.C. Notermans4, A.J. van der Kooi5, I.S.J. Merkies6,7, B.C. Jacobs1,3, P.A. van Doorn1 1Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 2Department of Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands 3Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 4Department of Neurology,…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) The PATH Study was a trial that investigated immunoglobulin treatment infused with a pump into the tissue under the skin (subcutaneously). There are several advantage of subcutaneous over intravenous treatment, e.g. patients or their caregivers can treat themselves at home, there are less severe…
A new treatment with compliment inhibition improves motor function in Guillain- Barré syndrome: Japanese eculizumab trial for Guillain- Barré syndrome (JET-GBS) Recent basic studies on the pathophysiology of Guillain- Barré syndrome (GBS) have shown that complement activation has a major role on peripheral nerve damage in GBS. Eculizumab (Alexion Pharmaceuticals Inc) is a humanized monoclonal antibody…
IgM paraprotein associated polyneuropathy is a slowly progressive disease with numbness or tingling of arms and legs and severe imbalance. Occasionally, tremors and weakness are present. These symptoms are disabling, but difficult to measure. In addition, the disease is relatively rare, not very well-known, and there is no cure available. The IMAGiNe study aims to…
2017 GBS|CIDP Foundation Grant Awardees (#1) Title of the project: Enhance Peripheral Nerve Repair by Modulating Macrophage Subsets Investigator: Gang Zhang, M.D; Ph.D Assistant Professor of Neurology University of Texas, Health Sciences Center at Houston Synopsis: Intravenous immunoglobulin (IVIg) is now the first-line therapy for Guillain-Barré syndrome (GBS). However, there are many disadvantages including high cost, supply…
GBS|CIDP Foundation International 2017 Benson Clinical Research Fellowship The GBS|CIDP Foundation International is pleased to announce a competition for the second Benson Clinical Research Fellowship. The aim of the scheme is to provide funds (up to $150k per year for three years) to enable clinicians or non-clinical scientists in training or having recently completed training…
Largest Ever CIDP Clinical Study Completed PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy KING OF PRUSSIA, Pa. – 01 March 2017 – Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as PATH (Polyneuropathy And Treatment…
Dr. Kenneth C. Gorson, MDPresident Elect GBS|CIDP Foundation International Global Medical Advisory BoardGuillain-Barre syndrome (GBS)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Medical Research: What is Guillain-Barré Syndrome? What are the main symptoms?Dr. Gorson: Guillain-Barré Syndrome (GBS) is an immune mediated disorder affecting the peripheral motor and sensory nerves and nerve roots, and is the most common cause…
Nursing Researchers from the University of Kansas School of Nursing are performing a research study with participants who have had a moderate to severe case of Guillain-Barre’ syndrome.
NARBERTH, Pa., Nov. 11, 2014 /PRNewswire/ — The GBS|CIDP Foundation International has announced the recipient of the first Benson Fellowship. This year’s winner is Dr. Ruth Huizinga, from Rotterdam, The Netherlands. Ruth presented her project, “High innate responsiveness to microbial triggers predisposing to the Guillain- Barre’ syndrome: identification of genetic causal variants” at the Foundation’s 13th International…
The Board of the Peripheral Nerve Society is proud to announce that at the 2015 Meeting in Quebec City, Canada, the Alan J. Gebhart – Peripheral Nerve Society Prize for Excellence in Peripheral Nerve Research will be given for the first time.
The GBS CIDP Foundation International is pleased to announce a competition for the first Benson Clinical Research Fellowship. The aim of the scheme is to provide funds (up to $150k per year for three years) to enable clinicians or non-clinical scientists in training or having recently completed training to engage in a substantial research project…
Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria from Brain, A Journal of Neurology.
NARBERTH, PA, November 8, 2013 /PRNewswire/ – The GBS/CIDP Foundation International has established the Benson Fellowship to fund Peripheral Neuropathy Fellowships in honor of Robert Benson, a survivor of Guillain-Barre’ Syndrome, and his wife Estelle Benson. The Foundation voted to endow over $1,600,000 of its financial resources to initially fund the Fellowship. The purpose of the Benson…
Spotlight
